Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2022-04-20 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
关于2019年限制性股票激励计划预留授予部分第二个解除限售期解除限售条件成就的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the unlocking of restricted shares under a 2019 restricted stock incentive plan by the company Xiamen Aide Bio-Pharmaceutical Technology Co., Ltd. It includes information about the approval process, performance conditions, number of shares unlocked, opinions from the board, independent directors, supervisory board, legal counsel, and financial advisors. The document is not a financial report, earnings release, or annual report, but rather a formal announcement about the status of a stock incentive plan and the unlocking of shares. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about share incentive plan conditions and related corporate governance matters, not a direct financial report or capital change announcement. The document length is over 6000 characters and contains substantive content, but it is not a report itself, nor a simple announcement of a report publication. Therefore, the best classification is Regulatory Filings (RNS).
2022-04-20 Chinese
独立董事关于相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of the company regarding matters related to the repurchase and cancellation of restricted stock under the 2019 restricted stock incentive plan, and the conditions for lifting restrictions on certain stock grants. It references compliance with regulatory guidelines and company rules but does not contain financial statements or detailed financial data. The document is a formal opinion related to management decisions on stock incentives, which aligns with governance or management information rather than a full report or announcement of voting results. It is not a report publication announcement or a certification letter. Given the content focuses on board-related decisions and opinions, the best fitting category is Board/Management Information (MANG). The document length is short (1053 characters), and it is not a report itself but an opinion statement from directors on management matters.
2022-04-20 Chinese
关于与阿斯利康达成靶向药物临床研究合作的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a cooperation agreement between the company and AstraZeneca on clinical research collaboration for targeted drugs. It details the nature of the collaboration, the parties involved, and the expected impact on the company. There is no financial data, no report attached or referenced as published, and no mention of a shareholder meeting or voting results. The document is a regulatory announcement about a business cooperation agreement, which does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a merger or acquisition, nor a capital or financing update. Given the content and length (1431 characters), it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2022-04-18 Chinese
关于使用部分闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the use of idle funds for cash management, including details about the investment purpose, amount, risk control measures, and approvals. It is a formal disclosure about a financing or capital management activity, not a financial report or earnings release. The document is relatively short (2201 characters) and does not contain financial statements or detailed financial data. It is not a report publication announcement since it contains substantive information about the capital use decision. The content fits best under Capital/Financing Update (CAP) as it relates to the company's financing activities and capital management plans.
2022-04-11 Chinese
2021年年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised by the company during the year 2021. It includes specifics on the amount raised, usage, changes in investment projects, and compliance with regulatory requirements. The presence of detailed financial figures, project progress, and regulatory references indicates this is a specialized report on fundraising and capital usage rather than a general annual or quarterly report. The document is not a simple announcement or certification but contains substantive financial and operational data related to capital raised and its deployment. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2022-04-11 Chinese
2021年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2021 年度内部控制自我评价报告' which translates to '2021 Annual Internal Control Self-Evaluation Report'. It is a detailed report on the company's internal control evaluation for the year ending December 31, 2021. The content includes descriptions of internal control environment, risk assessment, control activities, information and communication, and internal supervision. It also discusses the evaluation criteria for internal control deficiencies and the company's conclusions on the effectiveness of internal controls. The document is comprehensive and contains substantive information about internal controls rather than just an announcement or certification. It is not a full annual report (10-K) but a specific internal control evaluation report. This type of document aligns best with an Audit Report / Information (AR) category, which includes standalone audit reports and internal control evaluations. Therefore, the appropriate classification is AR with high confidence. FY 2021
2022-04-11 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.